The emerging therapeutic role of probiotics in inflammatory bowel disease.
Nonpathogenic bacteria in a genetically susceptible individual play a suggestive role in the pathogenesis of inflammatory bowel disease (IBD). Probiotics are living organisms that exert a protective effect on intestinal mucosa. Although evidence supporting their use for inducing or maintaining remission of IBD remains limited, it may be reasonable to use probiotics as an adjunct to standard therapy for mild-to-moderate disease. Genetically modified probiotics may provide novel delivery methods of therapeutic payloads to inflamed intestinal mucosa. This review focuses on the emerging use of probiotics in the treatment of IBD.
Dr. Doman serves as Clinical Professor of Medicine at George Washington University School of Medicine in Washington, DC, where Drs. Chandler and Wollins are Fellows in Gastroenterology. Dr. Toles is also affiliated with George Washington University of Medicine, as is Dr. Borum, who serves as the Chief of the Division of Gastroenterology and Professor of Medicine.
Matthew
M
Chandler
Eric
E
Wollins
Anastasia
A
Toles
Marie
M
Borum
David B
DB
Doman